CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB), a biotechnology company developing novel neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders, said it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering its EVM401 Series of molecules intended for potential treatment of mental health conditions.
A Notice of Allowance is issued by the USPTO when the agency determines that a patent should be granted based on the submitted application.
The application, titled “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives,” will be the fourth patent issued for Enveric’s EVM401 Series. The claims included in the new patent are expected to expand the Company’s pipeline by covering additional potential neuroplastogenic, non-hallucinogenic molecules designed to address neuropsychiatric and addiction disorders for patients who currently have limited therapeutic choices.
“Enveric is pleased with this upcoming addition to its overall patent estate and the growing pipeline of potential EVM401 molecules. This expansion of Enveric intellectual property demonstrates the Company’s ability to develop next-generation, non-hallucinogenic neuroplastogens intended for potential treatment of neuropsychiatric conditions,” said Joseph Tucker, Ph.D., Director and CEO of Enveric.
